Open AccessRepurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats
Author(s) -
Zikra Zulfiqar,
Fawad Ali Shah,
Shagufta Shafique,
Abdullah Alattar,
Tahir Ali,
Arooj Mohsin Alvi,
Sajid Rashid,
Shupeng Li
Publication year - 2020
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s284471
Subject(s) - medicine , pharmacology , neuroprotection , drug repositioning , neuroinflammation , dabigatran , pitavastatin , brain ischemia , ischemia , anesthesia , drug , inflammation , atorvastatin , warfarin , atrial fibrillation
Stress-associated kinases are considered major pathological mediators in several incurable neurological disorders. Importantly, among these stress kinases, the c-Jun NH2-terminal kinase (JNK) has been linked to numerous neuropathological conditions, including oxidative stress, neuroinflammation, and brain degeneration associated with brain injuries such as ischemia/reperfusion injury. In this study, we adopted a drug repurposing/reprofiling approach to explore novel JNK3 inhibitors from FDA-approved medications to supplement existing therapeutic strategies.